Vividion Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.vividion.com
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06188208
- Locations
- 🇦🇺
Orange Health Service, Orange, New South Wales, Australia
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05954312
- Locations
- 🇪🇸
START Barcelona Hospital HM Nou Delfos, Barcelona, Spain
🇪🇸START Madrid CIOCC, Madrid, Spain
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
© Copyright 2024. All Rights Reserved by MedPath